News

Shannon Westin, MD, and colleagues analyze the results from the phase 3 DUO-E trial, which examined the effectiveness of immunotherapy + carboplatin/paclitaxel on progression-free survival for patients with endometrial cancer.

Study on real-world data on patients with chronic lymphocytic leukemia investigated the outcomes for both Black and White patients.

The Journal of Clinical Pathways editorial team is pleased to announce that effective immediately, all submissions to our journal should be uploaded to our new online manuscript submission service, Editorial Manager.

The use of molecular profiling for targeted treatments has shown a significant improvement in survival outcomes for patients with biliary tract cancer, according to a new study based on real-world evidence.

Zanidatamab, a bispecific antibody targeting 2 distinct HER2 epitopes, demonstrates meaningful clinical benefit with a manageable safety profile among patients with refractory, HER2-positive unresectable, locally advanced or metastatic...

The Food and Drug Administration (FDA) has granted approval for the use of pembrolizumab in conjunction with gemcitabine and cisplatin for locally advanced unresectable or metastatic biliary tract cancer (BTC). This decision, announced on...

Results from NCCN's recent survey of cancer centers reveals a persisting shortage of chemotherapy drugs within the US, with 72% of centers reporting a shortage of carboplatin and 59% facing challenges with obtaining cisplatin.

Robin Yabroff, PhD, MBA, and Michael T. Halpern, MD, PhD, MPH, examine the documentation of cost of care discussions between physicians and patients with non–small cell lung cancer and melanoma.

Dr Doshi and colleagues measured the impact of medically integrated pharmacies on prescription medication abandonment rates.

Puneeth Indurlal, MD, MS, and colleagues examined the impact of lower cost alternative drugs or biosimilars on the cost of key cancer drugs.